FLGT Fulgent Genetics: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The EV/EBITDA valuation trend for Fulgent Genetics, Inc. (FLGT) reflects the dynamics of the company's partnerships with the public sector and clinics. Long-term contracts with medical networks support margin stability, although stricter FDA regulations and falling demand for COVID tests have reduced client inflow. The 0.00 mark indicates the business value relative to operating profit, helping to assess the asset's investment attractiveness.
Financial and market metric breakdowns for fulgentgenetics.com (FLGT)
- stock price and consensus target price:
- company stock capitalization data:
- book value of equity indicators:
- company liabilities and liquidity data:
Total Debt to Capital Fulgent Genetics, Inc.|FLGT - Long-Term Liabilities to Equity|Short-Term Debt to Equity Ratio Fulgent Genetics|FLGT - Company Aggregate Debts|Debt to Book Capitalization Ratio Fulgent|FLGT - Company Long-Term Debt|Company Short-Term Debts Fulgent Genetics|Quick Ratio fulgentgenetics.com
- financial results and valuation multiples details:
FLGT - Company Net Income|Expected Profit Fulgent Genetics, Inc.|FLGT - Price to Earnings Multiple|Projected Price to Earnings Fulgent Genetics, Inc.|FLGT - Company Value to Earnings Growth Ratio|Enterprise Value to EBITDA Ratio Fulgent|FLGT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Fulgent Genetics|FLGT - Net earnings per share for the trailing year|Quarterly EPS earnings growth fulgentgenetics.com|FLGT - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Fulgent Genetics, Inc.
Fundamental company analysis:FLGT (Fulgent Corp)
Given the low cyclicality of genetic diagnostics at Fulgent Genetics, Inc. (FLGT), the EV/EBITDA multiple on the time chart demonstrates the resilience of the business value relative to its operating profit. This indicator aggregates market capitalization and net debt, dividing them by earnings before depreciation and amortization, which allows an investor to assess the actual payback period of the asset while accounting for the debt load.
Who Fulgent Genetics, Inc. competes with
Agilent Tech - Enterprise Value to EBITDA Ratio|Quest Corp (DGX) - Company Value to EBITDA|ILMN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio exactsciences.com EXAS|RVTY: EV/EBITDA Multiple|BIO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Anbio Tech|Nordion (SHC) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple QDEL|OPK: Company Value to Operating Income Before Depreciation Ratio|CareDx Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Maravai LifeSciences Holdings MRVI|LAB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CTKB: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OSUR: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Exagen XGN|MDXH (MDxHealth) - EV/EBITDA Multiple|Company Value to EBITDA Lucid Diagnostics, Inc. LUCD|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prenetics Global (PRE)|imdxinc.com - Enterprise Value to Operating Income Before Depreciation|Trinity Biotech - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio PRPH (prophaselabs.com)|AIMD: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CODX (Co-Diagnostics Inc)|HSCS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Biomerica Inc BMRA|CDIO (Cardio Diagnostics Holdings Inc.) - EV/EBITDA Multiple|Company Value to EBITDA onconetix.gcs-web.com ONCO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Virax Biolabs (VRAX)|Bluejay Diagnostics Inc - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AWH (Vermillion)|Accelerate Diagnostics Inc (AXDX) - Company Value to EBITDA|CNTG: Enterprise Value to EBITDA Ratio|Enzo Biochem, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|FRES: EV/EBITDA Multiple|GENE - Total Company Value to Operating Income Before Depreciation Ratio|ME (23andMe Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Psychemedics Inc (PMD)
